ClickPET

ClickPET offers technical solutions for simplifying the production of disease specific biomolecule-based radiopharmaceuticals for positron emission tomography (PET) for aiding patient selection, cancer staging and disease follow-up by diagnostic imaging. The...
R2therapies Oy

R2therapies Oy

R2therapies Oy has discovered a novel and scientifically surprising blood-based biomarker to identify people at risk of developing dementia. The company aims to to develop an in-vitro diagnostic method compatible with primary healthcare for dementia-risk screening....
AarogyaAI

AarogyaAI

AarogyaAI’s vision is to make precision diagnosis for antimicrobial resistance accessible at the point of care by harnessing the powers of genomics and artificial intelligence. The aim is to reduce the incidence and spread of antimicrobial-resistant infections and...

Moncyte

Efficient lowering of blood cholesterol is pivotal in reducing the risk for heart attack and stroke, the most frequent causes of death globally. Different cholesterol-lowering drugs are available, but it is difficult to find an optimal treatment strategy for each...
NADMED Oy

NADMED Oy

The biology and key role of NAD molecules in human metabolism has been well known for decades, but measuring them has been devilishly difficult. NADMED has now brought to market an accurate, fast, scalable, and well protected method to do just that. The assay enables...